Demographics and treatment trends in the largest cohort of patients with Down syndrome and hidradenitis suppurativa

Int J Dermatol. 2024 Aug;63(8):e180-e181. doi: 10.1111/ijd.17261. Epub 2024 May 23.

Authors

Diem-Phuong D Dao¹, Catherine E Lyons², Aaron D Smith², Sara K Lamb³, Haley B Naik⁴, Richard Hal Flowers⁵

Affiliations

¹ School of Medicine, Virginia Commonwealth University, Richmond, VA, USA.
² School of Medicine, University of Virginia, Charlottesville, VA, USA.
³ Department of Dermatology, Virginia Commonwealth University, Richmond, VA, USA.
⁴ Department of Dermatology, University of California, San Francisco, San Francisco, CA, USA.
⁵ Department of Dermatology, University of Virginia, Charlottesville, VA, USA.

PMID: 38780080
DOI: 10.1111/ijd.17261

No abstract available

Keywords: Down syndrome; biologics; hidradenitis suppurativa; surgery; treatment; trisomy 21.

Publication types

Letter

MeSH terms

Adolescent
Adult
Anti-Bacterial Agents / therapeutic use
Child
Cohort Studies
Down Syndrome* / complications
Down Syndrome* / epidemiology
Female
Hidradenitis Suppurativa* / complications
Hidradenitis Suppurativa* / epidemiology
Hidradenitis Suppurativa* / therapy
Humans
Male
Middle Aged
Young Adult

Substances

Anti-Bacterial Agents